Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...

Shortly after, Novo Nordisk's CEO Mike Doustdar signaled the company is "all in" on the forthcoming launch of oral semaglutide, emphasizing robust supply readiness ahead of the anticipated year-end ...

A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...

Lilly's next-generation obesity shot is starting to look like the company's most powerful swing yet in a market investors expect to reshape global healthcare economics. After releasing late-stage data ...

Ozempic has been approved for type-2 diabetes, while Novo Nordisk’s other global blockbuster Wegovy is targeted at obesity.

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...